Transient left bundle branch block associated with favipiravir treatment for coronavirus infection.

The coronavirus disease 2019 (COVID-19) may lead to a wide spectrum of clinical manifestations ranging from asymptomatic to symptomatic by having targets on various tissues such as lung parenchyma and myocardium (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). As an RNA-dependent RNApolymerase inhibitor, favipiravir has been proposed as a treatment in clinical studies done during the pandemic period (Furuta et al., Antiviral Res. 100(2):446-454, 2013). Although favipiravir is generally a safe medication, it may rarely cause cardiac adverse effects (Shahrbaf et al., Cardiovasc Hematol Disord Drug Targets. 21(2):88-90, 2021). To the best of our knowledge, favipiravir has not been reported to cause left bundle branch block (LBBB). © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Citation

Siralp Bostan, Gizem Vural, Dilara Ecren Alaeddinoğlu, Ferit Onur Mutluer, Henry Huang, Tolga Aksu. Transient left bundle branch block associated with favipiravir treatment for coronavirus infection. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing. 2023 Sep;66(6):1321-1322

Mesh Tags

Substances

PMID: 37099218

search → result